bioAffinity Technologies, Inc.
$2.69
▼
-1.51%
2026-04-21 05:39:01
bioaffinitytech.com
NCM: BIAF
Explore bioAffinity Technologies, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$12.87 M
Current Price
$2.69
52W High / Low
$17.44 / $0.69
Stock P/E
—
Book Value
$1.62
Dividend Yield
—
ROCE
-131.93%
ROE
-3.02%
Face Value
—
EPS
$-8.66
Exp Qtr EPS
—
Sector
Healthcare
Industry
Diagnostics & Research
Employees
57
Beta
-0.81
Debt / Equity
15.95
Current Ratio
2.6
Quick Ratio
2.58
Forward P/E
-5.58
Price / Sales
2.45
Enterprise Value
$9.77 M
EV / EBITDA
-0.97
EV / Revenue
1.58
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Veracyte, Inc. | $33.45 | 39.66 | $2.63 B | — | 5.82% | 5.34% | $50.71 / $22.61 | $16.5 |
| 2. | Medpace Holdings, Inc. | $513.23 | 33.75 | $14.67 B | — | 84.68% | 70.23% | $628.92 / $250.05 | $16.18 |
| 3. | Mettler-Toledo International Inc. | $1,328.56 | 31.6 | $26.93 B | — | 44.48% | -1154.87% | $1,525.17 / $962.54 | $-1.16 |
| 4. | Inotiv, Inc. | $0.29 | — | $9.46 M | — | -17.26% | -49.76% | $3.32 / $0.22 | $3.17 |
| 5. | BillionToOne, Inc. | $86.97 | 489.81 | $3.65 B | — | 2.74% | 2.3% | $138.7 / $61.96 | $10.48 |
| 6. | Danaher Corporation | $189.21 | 37.67 | $133.79 B | 0.82% | 6.12% | 7.05% | $242.8 / $180.03 | $74.32 |
| 7. | GeneDx Holdings Corp. | $69.71 | — | $1.92 B | — | -3.15% | -7.6% | $170.87 / $55.17 | $10.54 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 1.54 M | 1.45 M | 1.27 M | 1.85 M | 2.21 M | — |
| Operating Profit | -3.19 M | -2.29 M | -2.52 M | -2.63 M | -2.95 M | — |
| Net Profit | -3.14 M | -5.05 M | -4.06 M | -2.66 M | -2.97 M | — |
| EPS in Rs | -0.7 | -1.12 | -0.9 | -0.59 | -0.66 | -4.84 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 6.11 M | 9.36 M | 2.53 M | 0 M |
| Operating Profit | -10.63 M | -8.95 M | -7.97 M | -4.01 M |
| Net Profit | -14.91 M | -9.04 M | -7.94 M | -8.15 M |
| EPS in Rs | -3.31 | -2.01 | -1.76 | -1.81 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 10.96 M | 6.51 M | 8.22 M | 12.18 M |
| Total Liabilities | 3.68 M | 3.91 M | 3.37 M | 1.14 M |
| Equity | 7.28 M | 2.6 M | 4.86 M | 11.04 M |
| Current Assets | 7.57 M | 2.7 M | 3.97 M | 11.96 M |
| Current Liabilities | 2.91 M | 3.1 M | 2.25 M | 1.14 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -9.33 M | -7.26 M | -6.04 M | -4.07 M |
| Investing CF | -0.06 M | -0.08 M | -2.21 M | -0.22 M |
| Financing CF | 14.73 M | 5.63 M | -0.34 M | 14.34 M |
| Free CF | -9.39 M | -7.34 M | -6.06 M | -4.29 M |
| Capex | -0.06 M | -0.08 M | -0.02 M | -0.22 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 269.68% | 52627.44% | — | — |
| Earnings Growth % | -13.89% | 2.66% | — | — |
| Profit Margin % | -96.56% | -313.41% | -169771.25% | — |
| Operating Margin % | -95.64% | -314.84% | -83511.51% | — |
| Gross Margin % | 36.09% | 31.26% | 90.28% | — |
| EBITDA Margin % | -88.98% | -301.26% | -116777.68% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-09-19 | 1:0.0333333 |